فایل ورد (word) مقاله Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin’s Lymphoma: a Single Institute Experience دارای 6 صفحه می باشد و دارای تنظیمات در microsoft word می باشد و آماده پرینت یا چاپ است
فایل ورد فایل ورد (word) مقاله Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin’s Lymphoma: a Single Institute Experience کاملا فرمت بندی و تنظیم شده در استاندارد دانشگاه و مراکز دولتی می باشد.
توجه : در صورت مشاهده بهم ريختگي احتمالي در متون زير ،دليل ان کپي کردن اين مطالب از داخل فایل ورد مي باشد و در فايل اصلي فایل ورد (word) مقاله Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin’s Lymphoma: a Single Institute Experience،به هيچ وجه بهم ريختگي وجود ندارد
بخشی از متن فایل ورد (word) مقاله Efficacy and Safety of First Line Vincristine with Doxorubicin, Bleomycin and Dacarbazine (ABOD) for Hodgkin’s Lymphoma: a Single Institute Experience :
سال انتشار : 2014
تعداد صفحات :6
Background: ABVD (doxorubicin, bleomycin, vinblastine (Vb) and dacarbazine) is the standard regimen inHodgkin’s lymphoma (HL).Vincristine (O) is a mitotic spindle agent like Vb. We aimed to evaluate the efficacyand safety of O as a part of ABOD in HL. Materials and Methods: Patients who had ABOD were enrolled. StageI-II HL were evaluated for unfavorable risk factors according to NCCN. National Cancer Institute CommonToxicity Criteria was used for toxicity. Results: Seventy-nine HL patients in our center between 2003 and 2007were evaluated retrospectively. Median follow-up was 54 months. Most of the patients were male in their thirddecade. Median ABOD cycles were 6 (2-8). Primary refractory disease rate was 17.7% whereas it was 5.1% forearly relapse and 5.1% for late relapse disease. Response rates were as 82.3% for complete response, 11.4%for partial response, 5.1% for stable disease and 1.3% for progressive disease. Half of relapsed patients hadautologous stem cell transplantation. Estimated 5-year failure-free survival was 71% and significantly longerin early stage patients without risk factors, bulky disease or radiotherapy (RT) (p=0.05, p<0.0001, p=0.02;respectively). Estimated 5-year overall survival was 74% and significantly longer in those who had no RT(p=0.001). Dose modification rate was 5.1% and chemotherapy delay rate was 19%. There were no toxicityrelateddeaths. Conclusions: ABOD seems to be effective with managable toxicity in HL, even in those with poorprognostic factors.